310 related articles for article (PubMed ID: 28060055)
21. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
22. Familial atypical multiple mole melanoma (FAMMM) syndrome: history, genetics, and heterogeneity.
Lynch HT; Shaw TG
Fam Cancer; 2016 Jul; 15(3):487-91. PubMed ID: 26892865
[TBL] [Abstract][Full Text] [Related]
23. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein.
Sun S; Pollock PM; Liu L; Karimi S; Jothy S; Milner BJ; Renwick A; Lassam NJ; Hayward NK; Hogg D; Narod SA; Foulkes WD
Int J Cancer; 1997 Nov; 73(4):531-6. PubMed ID: 9389568
[TBL] [Abstract][Full Text] [Related]
24. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect.
Auroy S; Avril MF; Chompret A; Pham D; Goldstein AM; Bianchi-Scarrà G; Frebourg T; Joly P; Spatz A; Rubino C; Demenais F; Bressac-de Paillerets B;
Genes Chromosomes Cancer; 2001 Nov; 32(3):195-202. PubMed ID: 11579459
[TBL] [Abstract][Full Text] [Related]
25. Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway.
Levin T; Mæhle L
Fam Cancer; 2017 Apr; 16(2):257-265. PubMed ID: 27804060
[TBL] [Abstract][Full Text] [Related]
26. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
[TBL] [Abstract][Full Text] [Related]
28. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
[TBL] [Abstract][Full Text] [Related]
29. Is there a role for genetic testing in patients with melanoma?
Kefford RF; Mann GJ
Curr Opin Oncol; 2003 Mar; 15(2):157-61. PubMed ID: 12601281
[TBL] [Abstract][Full Text] [Related]
30. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
31. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
Holland EA; Schmid H; Kefford RF; Mann GJ
Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
[TBL] [Abstract][Full Text] [Related]
32. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk.
Aspinwall LG; Stump TK; Taber JM; Drummond DM; Kohlmann W; Champine M; Leachman SA
Transl Behav Med; 2018 Jan; 8(1):29-43. PubMed ID: 29385581
[TBL] [Abstract][Full Text] [Related]
33. [CDKN2A-mutation in a family with hereditary malignant melanoma].
Djursby M; Wadt K; Lorentzen H; Borg A; Gerdes AM; Krogh L
Ugeskr Laeger; 2014 Sep; 176(40):. PubMed ID: 25294512
[TBL] [Abstract][Full Text] [Related]
34. Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
Pellegrini C; Maturo MG; Martorelli C; Suppa M; Antonini A; Kostaki D; Verna L; Landi MT; Peris K; Fargnoli MC
Melanoma Res; 2017 Jun; 27(3):258-267. PubMed ID: 28146043
[TBL] [Abstract][Full Text] [Related]
35. High- and low-penetrance cutaneous melanoma susceptibility genes.
Fargnoli MC; Argenziano G; Zalaudek I; Peris K
Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
[TBL] [Abstract][Full Text] [Related]
36. Rarity of CDK4 germline mutations in familial melanoma.
Goldstein AM; Chidambaram A; Halpern A; Holly EA; Guerry IV D; Sagebiel R; Elder DE; Tucker MA
Melanoma Res; 2002 Feb; 12(1):51-5. PubMed ID: 11828258
[TBL] [Abstract][Full Text] [Related]
37. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants.
Puntervoll HE; Yang XR; Vetti HH; Bachmann IM; Avril MF; Benfodda M; Catricalà C; Dalle S; Duval-Modeste AB; Ghiorzo P; Grammatico P; Harland M; Hayward NK; Hu HH; Jouary T; Martin-Denavit T; Ozola A; Palmer JM; Pastorino L; Pjanova D; Soufir N; Steine SJ; Stratigos AJ; Thomas L; Tinat J; Tsao H; Veinalde R; Tucker MA; Bressac-de Paillerets B; Newton-Bishop JA; Goldstein AM; Akslen LA; Molven A
J Med Genet; 2013 Apr; 50(4):264-70. PubMed ID: 23384855
[TBL] [Abstract][Full Text] [Related]
38. Melanoma candidate genes CDKN2A/p16/INK4A, p14ARF, and CDK4 sequencing in patients with uveal melanoma with relative high-risk for hereditary cancer predisposition.
Abdel-Rahman MH; Pilarski R; Massengill JB; Christopher BN; Noss R; Davidorf FH
Melanoma Res; 2011 Jun; 21(3):175-9. PubMed ID: 21412176
[TBL] [Abstract][Full Text] [Related]
39. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations.
Bishop JA; Wachsmuth RC; Harland M; Bataille V; Pinney E; MacK P; Baglietto L; Cuzick J; Bishop DT
J Invest Dermatol; 2000 Jan; 114(1):28-33. PubMed ID: 10620111
[TBL] [Abstract][Full Text] [Related]
40. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families.
Mantelli M; Barile M; Ciotti P; Ghiorzo P; Lantieri F; Pastorino L; Catricalà C; Torre GD; Folco U; Grammatico P; Padovani L; Pasini B; Rovini D; Queirolo P; Rainero ML; Santi PL; Sertoli RM; Goldstein AM; Bianchi-Scarrà G; ;
Am J Med Genet; 2002 Jan; 107(3):214-21. PubMed ID: 11807902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
